David R. Epstein Sells 370 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 370 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $53.31, for a total transaction of $19,724.70. Following the completion of the sale, the director now directly owns 27,524 shares in the company, valued at $1,467,304.44. This trade represents a 1.33 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Tempus AI Stock Performance

Shares of TEM stock traded up $7.33 during trading hours on Wednesday, hitting $69.18. 22,552,156 shares of the company’s stock traded hands, compared to its average volume of 11,320,281. The stock’s fifty day simple moving average is $44.20 and its two-hundred day simple moving average is $48.58. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $79.49. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Institutional Trading of Tempus AI

Large investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC bought a new position in Tempus AI in the 2nd quarter valued at $633,000. Millennium Management LLC purchased a new position in shares of Tempus AI in the second quarter worth $8,067,000. The Manufacturers Life Insurance Company purchased a new position in Tempus AI during the 2nd quarter worth approximately $946,000. Carnegie Investment Counsel acquired a new stake in Tempus AI during the third quarter worth about $7,936,000. Finally, Exchange Traded Concepts LLC purchased a new position in shares of Tempus AI in the 3rd quarter valued at about $3,458,000. 24.22% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on TEM. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and lifted their price objective for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research note on Tuesday, January 14th. Loop Capital dropped their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Wolfe Research started coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Finally, Guggenheim began coverage on shares of Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Tempus AI currently has a consensus rating of “Moderate Buy” and a consensus target price of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.